-
About
Mass General- Hospital Overview
- Why Mass General
- In the Local & Global Community
- Massachusetts General Physicians Organization
- Multimedia
- News & Events
- Support Mass General
- Conditions
& Treatments- View All Conditions & Treatments
- View by Medical Category:
- Centers
& Services- Care Centers
- Departments
- Anesthesia, Critical Care
& Pain Medicine - Dermatology
- Emergency Medicine
- Imaging
- Medicine
- Molecular Biology
- Neurology
- Neurosurgery
- Obstetrics & Gynecology
- Anesthesia, Critical Care
- Facilities & Amenities
- Patient & Family Services
- Research
- View All Research Centers & Labs
- Research at Mass General
- Research News & Events
-
Clinical
Trials - Education
& Training- View All Fellowships, Residencies & CME
- Specialized Education & Training
- Education & Training Calendar
- Career
Opportunities
Amir T. Fathi, MD
Instructor of Medicine
- Phone: 617-724-1124
- Departments
- Hematology/Oncology
- Department of Medicine
Specialties
- Cancer Center
- Leukemia
- Clinical Interests
- Acute myelogenous leukemia
- Acute lymphocytic leukemia
- Chronic myelogenous leukemia
- Myeloproliferative diseases
- Myelodysplastic syndrome (MDS)
- Locations
- Boston: Massachusetts General Hospital
- Medical Education
- MD, Yale University School of Medicine
- Residency, Massachusetts General Hospital
- Fellowship, Johns Hopkins Hospital
- Board Certifications
- Internal Medicine, American Board of Internal Medicine
- Hematology, American Board of Internal Medicine
- Medical Oncology, American Board of Internal Medicine
- Gender
- Male
- Foreign Languages
- Persian/Farsi
- Patient Age Group
- Adult
- Accepting New Patients
- Yes
Publications
Fathi AT, Arowojolu O, SwinnenI, Sato T, Rajkhowa T, Small D, Marmsater F,Robinson JE, Gross SD, Martinson M, Allen S,Kallan N, and Levis M. PIM1: A potential therapeutic target forFLT3/ITD AML. Submitted for publication.
Fathi AT, GrantS, Karp JE. Exploiting cellular pathways to develop new treatment strategiesfor AML. Cancer Treatment Reviews, 2010,Jan 5.
Fathi AT,Karp JE. New Agents in AML: Beyond Cytarabine and Anthracyclines. Current Oncology Reports (2009)11:346-352.
Fathi AT, LevisM. Lestaurtinib: a multi-targeted FLT3 inhibitor. Expert Rev. Hematol. February 2009, 2(1):17-26.
Hematology/Oncology BMT Program
100 Blossom Street
Boston, MA 02114
100 Blossom Street
Boston, MA 02114
Phone: 617-724-1124
- © 2013 Massachusetts General Hospital
- 55 Fruit Street, Boston, MA 02114
- Maps & Directions
- 617-726-2000
- TDD: 617-724-8800
